GRRMY.US Gerresheimer AG
- Market cap
- USD 1.17B
- P/E
- -
- P/B
- 1.10x
- ROE
- -41.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Feb 2026.
Is GRRMY.US undervalued?
Graham numberThe Graham number of Gerresheimer AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gerresheimer AG fundamental analysis
No fundamental analysis for Gerresheimer AG yet.
Gerresheimer AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and cont…
Full company profileGerresheimer AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Feb 28, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gerresheimer AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.39B | 1.42B | 1.50B | 1.82B | 1.99B | 1.99B | 2.32B | 1.90B |
| Gross Profit | 277M | 438M | 442M | 547M | 597M | 568M | 425M | 197M |
| Operating Income | 32.6M | 180M | 179M | 219M | 229M | 192M | -70.8M | -208M |
| EBITDA | 393M | 301M | 294M | 340M | 404M | 375M | 290M | 185M |
| Net Income | 80.8M | 88.6M | 83.8M | 96.1M | 116M | 82.3M | -320M | -393M |
| EPS | 2.57 | 2.82 | 2.67 | 3.06 | 3.36 | 2.38 | -9.27 | -11 |
| Balance Sheet | ||||||||
| Total Assets | 2.64B | 2.62B | 2.88B | 3.35B | 3.43B | 3.81B | 4.49B | 4.35B |
| Total Liabilities | 1.70B | 1.72B | 1.88B | 2.08B | 1.96B | 2.27B | 3.39B | 3.37B |
| Shareholders' Equity | 942M | 900M | 1.00B | 1.27B | 1.47B | 1.51B | 1.08B | 956M |
| Cash & Short-term Investments | 85.8M | 88.0M | 114M | 113M | 122M | 186M | 176M | 168M |
| Cash Flow | ||||||||
| Operating Cash Flow | 193M | 222M | 212M | 222M | 294M | 239M | 210M | 97.2M |
| Capital Expenditure | 165M | 174M | 206M | 257M | 328M | 370M | 308M | 257M |
| Free Cash Flow | 28.4M | 49.1M | 8.45M | -16.1M | -33.7M | -131M | -98.8M | -160M |
| Ratios | ||||||||
| ROE | 8.6% | 9.8% | 8.4% | 7.6% | 7.9% | 5.4% | -29.6% | -41.1% |
| ROA | 3.1% | 3.4% | 2.9% | 2.9% | 3.4% | 2.2% | -7.1% | -9.0% |
| Net Profit Margin | 5.8% | 6.2% | 5.6% | 5.3% | 5.8% | 4.1% | -13.8% | -20.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gerresheimer AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 9, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 39.3M | 1.25 | 40.8% |
| 2021 | EUR 39.3M | 1.25 | 46.8% |
| 2020 | EUR 39.3M | 1.25 | 44.4% |
| 2019 | USD 39.4M | 1.26 | 48.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Gerresheimer AG
Ownership data of Gerresheimer AG is not available yet.
Gerresheimer AG company profile
- Company name
- Gerresheimer AG
- Ticker
- GRRMY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 13,301
- Fiscal year end
- November
- Address
- Peter-Müller-Straße 3, Düsseldorf, Germany, 40468
- Phone
- 49 211 61 81 00
- Website
- gerresheimer.com
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.
Gerresheimer AG management
6- Mr. Wolf Uwe LehmannCFO & Member of the Management Board · born 1971
- Mr. Achim SchalkMember of the Management Board · born 1972
- Ms. Katja SchnitzlerGlobal Senior VP of People & Organization and Member of Supervisory Board · born 1981
- Mr. Guido PickertHead of Investor Relations
- Ueli UtzingerGroup Senior Director Marketing & Communication
- Mr. Hans-Norbert ToppHead of Moulded Glass Business Unit · born 1961